

**Section II (Remarks)**

In the Office Action, the Examiner has required restriction under the provisions of 35 U.S.C. 121 between:

I. Claims 1-8 and 26-30, drawn to a pharmaceutical composition comprising a compound of formula I, classified in class 435, subclass 243.

II. Claims 9-25, drawn to a method of treating or preventing bacterial ear infection using a compound of formula I, classified in class 435, subclass 243.

Applicant herewith elects Group (I), claims 1-8 and 26-30, drawn to a pharmaceutical composition comprising a compound of formula I, without traverse. Claims 1-8 and 26-30 read on the pharmaceutical composition comprising a compound of formula (I).

**CONCLUSION**

The Examiner is requested to favorably consider the foregoing, and, upon granting of the Petition to Revive, to responsively examine the application. If any issues require further resolution, the Examiner is requested to contact the undersigned attorney at (919) 419-9350 to discuss same.

Respectfully submitted,

\_\_\_\_\_/ david bradin /  
David Bradin  
Reg. No. 37,783  
Attorney for Applicants

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
Phone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney File No.: 4354-111

<p>The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284</p>
--